Masimo Co. (NASDAQ:MASI) Receives $194.80 Consensus Price Target from Analysts

Shares of Masimo Co. (NASDAQ:MASI) have been given an average recommendation of “Moderate Buy” by the six brokerages that are covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the company. The average twelve-month price target among brokerages that have issued ratings on the stock in the last year is $191.60.

MASI has been the topic of a number of recent research reports. Piper Sandler restated an “overweight” rating and set a $200.00 price target (down previously from $215.00) on shares of Masimo in a report on Wednesday. Raymond James reduced their price target on Masimo from $204.00 to $185.00 and set an “outperform” rating for the company in a research report on Wednesday. Wells Fargo & Company lowered their price objective on Masimo from $205.00 to $190.00 and set an “overweight” rating on the stock in a report on Wednesday. BTIG Research set a $193.00 target price on Masimo and gave the stock a “buy” rating in a report on Wednesday. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Masimo in a report on Thursday, April 10th.

Masimo Stock Up 2.3 %

Masimo stock opened at $157.18 on Tuesday. Masimo has a twelve month low of $101.61 and a twelve month high of $194.88. The company has a debt-to-equity ratio of 0.50, a quick ratio of 1.11 and a current ratio of 2.01. The firm has a market cap of $8.49 billion, a PE ratio of 108.40 and a beta of 1.23. The firm’s 50 day moving average price is $161.66 and its two-hundred day moving average price is $166.75.

Masimo (NASDAQ:MASI) last released its quarterly earnings data on Tuesday, May 6th. The medical equipment provider reported $1.36 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.24 by $0.12. Masimo had a return on equity of 14.98% and a net margin of 3.85%. The firm had revenue of $372.00 million during the quarter, compared to analysts’ expectations of $367.79 million. During the same quarter last year, the firm earned $0.77 earnings per share. The business’s revenue for the quarter was down 24.5% on a year-over-year basis. On average, research analysts predict that Masimo will post 4.1 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, COO Bilal Muhsin sold 30,000 shares of the company’s stock in a transaction on Monday, March 10th. The shares were sold at an average price of $167.49, for a total transaction of $5,024,700.00. Following the completion of the transaction, the chief operating officer now directly owns 24,172 shares in the company, valued at $4,048,568.28. This represents a 55.38 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Craig B. Reynolds sold 2,053 shares of the firm’s stock in a transaction on Friday, March 14th. The stock was sold at an average price of $166.13, for a total transaction of $341,064.89. Following the completion of the sale, the director now owns 16,581 shares in the company, valued at $2,754,601.53. This represents a 11.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 9.70% of the company’s stock.

Hedge Funds Weigh In On Masimo

Large investors have recently added to or reduced their stakes in the company. Smartleaf Asset Management LLC increased its position in shares of Masimo by 31.6% during the fourth quarter. Smartleaf Asset Management LLC now owns 250 shares of the medical equipment provider’s stock valued at $42,000 after purchasing an additional 60 shares during the period. EverSource Wealth Advisors LLC increased its holdings in Masimo by 40.0% in the 4th quarter. EverSource Wealth Advisors LLC now owns 224 shares of the medical equipment provider’s stock valued at $37,000 after buying an additional 64 shares during the period. Blue Trust Inc. raised its stake in shares of Masimo by 56.3% in the 4th quarter. Blue Trust Inc. now owns 197 shares of the medical equipment provider’s stock valued at $33,000 after buying an additional 71 shares in the last quarter. Xponance Inc. lifted its holdings in shares of Masimo by 1.1% during the 1st quarter. Xponance Inc. now owns 7,101 shares of the medical equipment provider’s stock worth $1,183,000 after acquiring an additional 76 shares during the period. Finally, Commonwealth of Pennsylvania Public School Empls Retrmt SYS boosted its position in shares of Masimo by 0.8% during the 4th quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 9,815 shares of the medical equipment provider’s stock valued at $1,622,000 after acquiring an additional 82 shares in the last quarter. Institutional investors and hedge funds own 85.96% of the company’s stock.

About Masimo

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.